Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 22 citing articles:

IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Astrid Van den Eynde, Laura Gehrcken, Tias Verhezen, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 27
Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective
Yunyi Wu, Yanchun Li, Yan Gao, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116132-116132
Open Access | Times Cited: 7
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
Ugochi Ebinama, Binsah George
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics
Xiaoyan Li, You Zhang, Jason C. Mixdorf, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268835-jnumed.124.268835
Closed Access
Immune checkpoints regulate acute myeloid leukemia stem cells
C. Bachmann, Adrian F. Ochsenbein
Leukemia (2025)
Open Access
CD70-targeted cancer theranostics: Progress and challenges
Weijun Wei, Viktor Grünwald, Ken Herrmann
Med (2025), pp. 100671-100671
Closed Access
Novel immunotherapies in the treatment of AML: is there hope?
Marion Subklewe, Veit Bücklein, David A. Sallman, et al.
Hematology (2023) Vol. 2023, Iss. 1, pp. 691-701
Closed Access | Times Cited: 10
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies
Daniel J. Chandra, Bernhard Alber, Jennifer N. Saultz
Cancers (2024) Vol. 16, Iss. 15, pp. 2615-2615
Open Access | Times Cited: 3
Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies
Luca Guarnera, Carlos Bravo‐Pérez, Valeria Visconte
Bioengineering (2023) Vol. 10, Iss. 10, pp. 1228-1228
Open Access | Times Cited: 8
CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GvHD
Kriti Verma, Wayne Croft, Sandra Margielewska-Davies, et al.
Blood Advances (2024) Vol. 8, Iss. 18, pp. 4900-4912
Open Access | Times Cited: 2
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
Thomas Müller, Carolin Tasser, Michael Tesar, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Harnessing Immune Response in Acute Myeloid Leukemia
Carola Riva, Chiara Vernarecci, Paola Minetto, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 5824-5824
Open Access | Times Cited: 6
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies
Evan C. Chen, Jacqueline S. Garcia
Acta Haematologica (2023) Vol. 147, Iss. 2, pp. 198-218
Open Access | Times Cited: 6
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling
Song Li, Dianze Chen, Huiqin Guo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
Francesca Kinsella, Maria A. L. Maroto, Justin Loke, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 6, pp. 2173-2183
Open Access | Times Cited: 1
Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia
Dan Wang, Jing He, Si‐Yang Maggie Liu, et al.
Cancer Letters (2024) Vol. 593, pp. 216970-216970
Open Access | Times Cited: 1
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells
Ugo Testa, Germana Castelli, Elvira Pelosi
Cancers (2024) Vol. 16, Iss. 21, pp. 3627-3627
Open Access
Combination Therapy Involving Azacitidine for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Juan Li, Shuying Fu, Chunmei Ye, et al.
Leukemia Research (2024) Vol. 148, pp. 107638-107638
Closed Access
Upregulated cholesterol biosynthesis facilitates the survival of methylation-retaining AML cells following decitabine treatment.
Danielle R. Bond, Sean M. Burnard, Kumar Uddipto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
Xiaohuan Peng, Futian Tang, Yanhong Li, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Immunotherapy of Acute Myeloid Leukemia: A Work in Progress
Matteo Molica, Salvatore Perrone, Marco Rossi
(2023)
Open Access | Times Cited: 1
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress
Matteo Molica, Salvatore Perrone, Costanza Andriola, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5060-5060
Open Access | Times Cited: 1
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
Amir T. Fathi
The Lancet Haematology (2023) Vol. 10, Iss. 11, pp. e868-e870
Closed Access
Page 1

Scroll to top